A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome

作者：Walker Brandon S; Jackson Brian R; LaGrave Danielle; Ashwood Edward R; Schmidt Robert L^*

来源：Prenatal Diagnosis, 2015, 35(5): 440-446.

DOI：10.1002/pd.4511

ObjectiveThe aim of this article is to determine the cost effectiveness of cell free DNA (cfDNA) as a replacement for integrated screening using a societal cost perspective.
MethodThis study used Monte-Carlo simulation with one-way and probabilistic sensitivity analysis.
ResultsCell free DNA is more effective and less costly than integrated screening. The incremental cost-effectiveness ratio for cfDNA relative to the integrated test was -$277955 per case detected (95th percent confidence interval -$881882 to $532785).
ConclusionCell free DNA screening is a cost-effective replacement for maternal serum screening when the lifetime costs of Down syndrome live births are considered. The adoption of cfDNA screening would save approximately $277955 for each additional case detected over integrated screening.

• 出版日期2015-5